Valuation: Integrity Applications, Inc.

Market Cap 20.03L 17.51L 16.09L 15L 28.45L 19Cr 28.88L 1.93Cr 75.1L 9.37Cr 75.18L 73.57L 32Cr P/E 2024 *
-
P/E 2025 -0.12x
Enterprise Value -19.34L -16.91L -15.54L -14.48L -27.47L -18Cr -27.89L -1.87Cr -72.51L -9.05Cr -72.6L -71.04L -31Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.06%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 59 -
Director of Finance/CFO 66 28/01/2025
Chief Operating Officer - 01/02/2025
Director TitleAgeSince
Director/Board Member 59 27/08/2024
Director/Board Member 56 25/08/2023
Chairman 63 13/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
+15.79%+10.00% - - 20.03L
+1.70%+7.41%+3.12%+8.46% 4.91TCr
+0.92%+6.21%+408.85%+607.44% 4.02TCr
+1.89%+11.06%+25.75%-7.89% 3.46TCr
+5.46%+8.10%+21.83%+66.94% 3.31TCr
+3.96%+6.07%+14.14%+37.68% 2.52TCr
+2.51%+4.94% - - 1.7TCr
+2.58%+7.24%+71.03%+132.17% 1.59TCr
+0.32%+0.58%+13.67%+19.09% 1.38TCr
-1.14%+7.52%+14.75%-30.83% 1.33TCr
Average +3.06%+5.99%+71.64%+104.13% 2.69TCr
Weighted average by Cap. +1.74%+6.31%+89.18%+131.90%

Financials

2024 2025
Net sales - -
Net income -2.26Cr -1.98Cr -1.82Cr -1.69Cr -3.21Cr -215.16Cr -3.26Cr -22Cr -8.47Cr -105.76Cr -8.48Cr -8.3Cr -364.44Cr -1.94Cr -1.69Cr -1.56Cr -1.45Cr -2.75Cr -184.6Cr -2.8Cr -19Cr -7.27Cr -91Cr -7.28Cr -7.12Cr -312.69Cr
Net Debt -53.5L -46.77L -42.98L -40.06L -75.99L -51Cr -77.14L -5.16Cr -2.01Cr -25Cr -2.01Cr -1.97Cr -86Cr -39.37L -34.42L -31.63L -29.48L -55.92L -37Cr -56.77L -3.8Cr -1.48Cr -18Cr -1.48Cr -1.45Cr -63Cr
Logo Integrity Applications, Inc.
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
Employees
-